Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy

Bibliography

• Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83(5):584-94
   PubMed Web of Science ®Google Scholar
• Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16(3):481-8
   PubMed Web of Science ®Google Scholar
• Peter G. The 7th Edition of TNM in lung cancer: what now? J Thorac Oncol 2009;4(6):671-3
   PubMed Web of Science ®Google Scholar
• Scheff RJ, Schneider BJ. Non-small-cell lung cancer: treatment of late stage disease: Chemotherapeutics and new frontiers. Semin Intervent Radiol 2013;30(2):191-8
   Google Scholar
• Ulivi P, Zoli W, Capelli L, et al. Target therapy in NSCLC patients: relevant clinical agents and tumor molecular characterization. Mol Clin Oncol 2013;1(4):575-81
   Google Scholar
• Al-Farsi A, Ellis PM. Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line. Front Oncol 2014;4:157
   PubMedGoogle Scholar
• Kamen BA, Smith AK. Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro. Cancer Chemother Pharmacol 2012;70(1):113-20
   PubMed Web of Science ®Google Scholar
• Thomas A, Maltzman J, Hassan R. Farletuzumab in lung cancer. Lung Cancer 2013;80(1):15-18
   PubMed Web of Science ®Google Scholar
• Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer. J Carcinog 2013;12:22
   PubMedGoogle Scholar
• Garin-Chesa P, Campbell I, Saigo PE, et al. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 1993;142(2):557-67
   PubMed Web of Science ®Google Scholar
• Nicolaides NC, Ebel W, Kline B, et al. Morphogenics as a tool for target discovery and drug development. Ann N Y Acad Sci 2005;1059:86-96
   PubMed Web of Science ®Google Scholar
• Ebel W, Routhier EL, Foley B, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 2007;7:6
   PubMedGoogle Scholar
• Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 2010;10(3):431-7
   PubMed Web of Science ®Google Scholar
• Farrell C, Schweizer C, Wustner J, et al. Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer. Cancer Chemother Pharmacol 2012;70(5):727-34
   PubMed Web of Science ®Google Scholar
• Marchetti C, Palaia I, Giorgini M, et al. Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. Onco Targets Ther 2014;7:1223-36
   PubMed Web of Science ®Google Scholar
• Konner JA, Bell-McGuinn KM, Sabbatini P, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 2010;16(21):5288-95
   PubMed Web of Science ®Google Scholar
• Kim KH, Jelovac D, Armstrong DK, et al. Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive epithelial ovarian cancer (EOC). J Clin Oncol 2012;30:abstract 5062
   Google Scholar
• Armstrong DK, Bicher A, Coleman RL C. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse [meeting abstracts]. J Clin Oncol 2008;26(Suppl 15):5500
   PubMedGoogle Scholar
• White AJ, Coleman RL, Armstrong DK, et al. Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study. J Clin Oncol 2010;28:abstract 5001
   Google Scholar
• A randomized, double-blind, placebo-controlled, phase 3 study to assess the efficacy and safety of weekly MORAb-003 in combination with carboplatin and taxane in subjects with platinum-sensitive ovarian cancer in first relapse. NCT00849667. Available from: http://clinicaltrials.gov/show/NCT00849667
   Google Scholar
• A randomized, double-blind, placebo-controlled, study of the safety and efficacy of farletuzumab in combination with a platinum containing doublet in chemotherapy-naїve subjects with stage IV adenocarcinoma of the lung. Available from: http://clinicaltrials.gov/show/NCT01218516
   Google Scholar
• Bronte G, Rolfo C, Giovannetti E, et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Oncol Hematol 2014;89(2):300-13
   PubMed Web of Science ®Google Scholar
• Di Fede G, Bronte G, Rizzo S, et al. Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors. Expert Opin Biol Ther 2011;11(11):1433-45
   PubMed Web of Science ®Google Scholar
• Bronte G, Terrasi M, Rizzo S, et al. EGFR genomic alterations in cancer: prognostic and predictive values. Front Biosci (Elite Ed) 2011;3:879-87
   PubMedGoogle Scholar
• Bronte G, Rizzo S, La Paglia L, et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev 2010;36(Suppl 3):S21-9
   PubMed Web of Science ®Google Scholar
• Rolfo C, Giovannetti E, Hong DS, et al. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treat Rev 2014;40(8):990-1004
   PubMed Web of Science ®Google Scholar
• Rolfo C, Raez LE, Bronte G, et al. BIBF 1120/nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. Expert Opin Investig Drugs 2013;22(8):1081-8
   PubMed Web of Science ®Google Scholar
• Franchina T, Amodeo V, Bronte G, et al. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol 2014;229(1):97-9
   PubMed Web of Science ®Google Scholar
• Liu Y, Yin TJ, Zhou R, et al. Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis. Cancer Chemother Pharmacol 2013;72(5):1125-32
   PubMed Web of Science ®Google Scholar
• Zhao R, Babani S, Gao F, et al. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin Cancer Res 2000;6(9):3687-95
   PubMed Web of Science ®Google Scholar
• Nutt JE, Razak AR, O’Toole K, et al. The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy. Br J Cancer 2010;102(3):553-60
   PubMed Web of Science ®Google Scholar